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loop 2 domain (ECL2) using a truncated competitive antagonist 
(CGRP8-37): Evidence for the dual involvement of ECL2 in the two-
domain binding model.  
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ABSTRACT: The second extracellular loop (ECL2) of the G 
protein-coupled receptor (GPCR) family is important for ligand-
interaction and drug discovery. ECL2 of the family B cardiopro-
tective CGRP receptor is required for cell signalling. Family B 
GPCR ligands have two regions; the N-terminus mediates recep-
tor activation and the remainder confers high-affinity binding. 
Comparing antagonism of CGRP8-37 at a number of point muta-
tions of ECL2 of the CGRP receptor, we show that the loop facili-
tates interaction with the N-terminal loop but also residues C-
terminal to this. This has implications for understanding family B 
GPCR activation and for drug design at the CGRP receptor. 
More than a third of all therapeutic compounds target 
members of the G protein-coupled receptor (GPCR) super-
family. Understanding how ligands bind to GPCRs is there-
fore key to modern molecular pharmacology. The second 
extracellular loop (ECL2) of the GPCR super-family is the 
largest and most structurally diverse of the ECLs and is 
vital for ligand binding and activation for almost all of 
these receptors [1-3]. Crystal structures of the largest sub-
family of GPCRs (family A) show ECL2 in a variety of 
conformations, including beta-sheets, alpha helices and 
unstructured loops [4-6]. Family B GPCRs includes a 
smaller group of pharmaceutically important peptide-
binding receptors. Conversely, the three available crystal 
structures of family B GPCRs suggest that ECL2 has no 
significant secondary structural components [7-9]. Despite 
this, every biochemical analysis done on the family B 
GPCR ECL2 regions have found it to be vital for the bind-
ing of the respective peptide ligands and the subsequent 
activation of various signalling pathways [10-12].  
 
Family B GPCRs are all activated by relatively small pep-
tide ligands (typically under 100 amino acids long). They 
have a diverse range of physiological effects (such as car-
dioprotection, bone resorption, migraine, digestion control, 
glucose homeostasis and steroid hormone responses), 
which has made them of considerable therapeutic interest 
[13]. These peptide ligands are thought to follow a broadly 
consistent binding mechanism, termed the two-domain 
model [14]. Briefly, the C-terminus of the ligand binds to 
the large extracellular N-terminus of its GPCR. This facili-
tates the binding of the N-terminus of the ligand to the ECL 
regions and transmembrane (TM) domain of the receptor. 
This in turn causes receptor activation and second messen-
ger signalling. It is not known exactly where the ligand N-
terminus binds or how that interaction results in the con-
formational changes that stabilise receptor activation. This 
information will help our understanding of ligand-binding 
and also provide a platform for the design of specific mole-
cules for individual receptor structures. 
 
One important member of the family B GPCRs is the 
CGRP receptor. This belongs to the calcitonin-like sub-
family and is of considerable therapeutic interest due to the 
highly potent vasodilatory properties of the CGRP neuro-
peptide ligand. CGRP has cardioprotective properties of 
potential beneficial use in heart failure and hypertension 
[15,16] and has been implicated in the induction of mi-
graine [17]. The CGRP receptor has also been studied ex-
tensively because of another unusual feature; it functions as 
an obligate heterodimer formed by a GPCR subunit (calci-
tonin receptor-like receptor; CLR) and a single TM span-
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ning protein called receptor activity modifying protein 1 
(RAMP 1) [18].  
 
In our recent alanine scan of the CGRP receptor, we substi-
tuted 24 residues of the ECL2 region and found that 14 had 
significant differences in receptor signalling [12]. The larg-
est differences occurred with mutation of residues in the N-
terminal half of the loop, although the supporting in silico 
modelling data predicted the involvement of C-terminal 
residues in receptor-ligand interactions. This alanine-
substitution analysis identified residues required for CGRP 
receptor function providing a platform for a more mecha-
nistic analysis of ECL2. In the present study, six key resi-
dues identified from the alanine scan of the CGRP receptor 
were selected to investigate the affinity of a truncated ver-
sion of CGRP missing the first seven residues (CGRP8-37). 
CGRP8-37 acts as a reversible, competitive antagonist with 
an affinity approximately 10-fold lower than full length 
CGRP. It is thought that CGRP adheres to the two-domain 
binding model whereby the 8-37 region of CGRP has a 
discrete binding region that facilitates a second binding 
event allowing the first seven residues of CGRP to act as 
the activation domain [14]. 
 
Specifically, we are asking whether the ability of CGRP8-37 
to antagonise a mutant receptor (where the interaction with 
the full length CGRP agonist is impaired) is reduced to the 
same degree as the potency of CGRP. If this the case, then 
it would imply that the mutated residue interacted with both 
CGRP and CGRP8-37. By contrast, if the effect of CGRP8-37 
is the same for wild type (WT) and mutant receptors, it 
follows that the mutated residue is interacting just with the 
first seven residues of CGRP (either directly or by affecting 
a CGRP-independent activation process of the receptor). 
As labelled CGRP8-37 is not readily available to allow a 
direct measure of its affinity, this is assessed indirectly by 
looking at the shift the antagonist causes in the concentra-
tion-response curve to CGRP. If the same parallel right-
ward shift is observed in both WT and mutant receptors, 
then the affinity and mode of antagonism is also the same. 
 
For this study, we have targeted receptor mutations that 
either had the biggest reduction in cAMP signalling 
(R274A, D280A and W283A) or those that were predicted 
to make ligand contacts in our earlier study (I284A, D287A 
and T288A) [12]. 
 
The binding affinity, expressed as Log Kd (pKd) for 
CGRP8-37 to the WT and mutant receptors was estimated 
either by the shift in the dose ratio where there was no sig-
nificant change in maximum response (Emax) in the pres-
ence of the antagonist (pKd = (Log{[CGRP8-37]/Dose-ratio 
-1} or by the method of Gaddum where the Emax was de-
pressed [19]. Cos 7 cells were transiently transfected with 
the WT or mutant receptor construct in a mammalian ex-
pression vector pcDNA3.1- (Invitrogen, UK) and co-
transfected with a pcDNA3/RAMP1 construct as described 
previously [12]. Cells were stimulated with CGRP agonist 
(over a concentration range of 10-12 M to 10-5 M) in the 
presence or absence of 10-7 M CGRP8-37 antagonist and 
cAMP was measured using the FRET-based Lance-assay as 
described [20]. 10-7 M CGRP8-37 was used as lower concen-
trations of CGRP8-37 gave CGRP activation curves that 
were poorly resolved from the control in the absence of 
antagonist; higher concentrations gave incomplete curves 
(data not shown).  
 
The signalling curves for this study are shown in figure 1. 
The Emax values of the alanine substitution receptor (+ 
CGRP8-37) were compared to a normalised alanine substitu-
tion receptor – CGRP8-37 (set to 100%) and compared using 
a one sample t test (table 1 and figure 2). The computed 
pKd values are shown in table 1. 
 
I284A resulted in a significant reduction in the affinity of 
CGRP8-37 (table 1). It is likely therefore that the reduction 
in cAMP signalling observed with the I284A mutant [12] is 
caused by a disruption of the receptor’s ability to interact 
with the CGRP 8-37 region. There was also a small reduc-
tion in the affinity for W283A. Conversely, the shift in the 
CGRP concentration-response curve caused by the CGRP8-
37 antagonist at the R274A, D280A, and T288A receptors 
was not significantly different to that seen for the WT 
CGRP receptor. This suggests that the deleterious effects 
on signalling of these mutants previously seen [12] is not 
mediated by the CGRP 8-37 region and therefore, stabilises 
direct or indirect interactions between the CGRP receptor 
and the first seven residues of CGRP (the activation do-
main). However, for all of these mutants as well as 
W283A, CGRP8-37 appeared to act non-competitively at the 
mutants, with significant reductions in Emax (Figure 2). 
D287A had no effect on CGRP potency, in contrast to our 
previous study [12]. 
The apparent change in mode of antagonism is unexpected. 
Caution is needed with this interpretation, as it was not 
possible to construct full concentration-response curves to 
CGRP in the presence of CGRP8-37 for the mutants with 
lower CGRP potency, as the required concentrations of 
CGRP would be impractical. However, when we fit “ex-
pected” concentration-response curves in accordance with 
competitive inhibition assuming a full Emax (dotted line 
graphs in figure 1), then the shift in the curve for CGRP for 
the mutant receptors would be even greater than for the WT 
receptors; i.e. the affinity for CGRP8-37 would have in-
creased. In either interpretation, these mutations give unex-
pected effects. 
There was no evidence of any non-competitive inhibition 
by CGRP8-37 on the WT receptor, even when cells were 
transfected with only 10% of the normal CLR/RAMP1 
cDNA (data not shown). Under these conditions, any re-
ceptor reserve will have been removed (the maximum 
stimulation of cAMP was reduced by 93%), which might 
otherwise mask non-competitive behaviour of antagonists. 
There was still a clear shift of the CGRP concentration re-
sponse curve in the presence of 10-7 M CGRP8-37 (shift 1.54 
± 0.35, n=3), but there was no significant change in the 
Emax in the presence of the antagonist (125 ± 25% of 
CGRP alone). 
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Of the residues examined in this study, only I284 is pre-
dicted to face bound CGRP in a model of CLR (Fig 3); 
interestingly it interacts with the 8-18 helix of the peptide. 
T288 may have a weak interaction with the extreme N-
terminus of CGRP, but the other residues face into the 
binding pocket. The model must be treated with caution, as 
we have not included RAMP1, but the findings are in 
agreement with our functional assays. We speculate that the 
R274, D280 and W283 and (to a lesser extent) T288 are 
important for maintaining the architecture of the peptide-
binding pocket. In support of this, there is a correlation 
between the reduction in CGRP potency at the mutants and 
the decrease in Emax in the presence of CGRP8-37 (Fig 2b). 
We suggest that when R274, D280 and W283 and T288 are 
mutated, residues 1-7 of CGRP no longer fit easily into this 
pocket, whereas CGRP8-37 binds relatively unimpaired. This 
may slow the association of CGRP to the mutated recep-
tors, resulting in apparent non-competitive inhibition with 
CGRP8-37 under the conditions of our assay.  
 
This work is the first mutational evidence to map the inter-
action of CGRP within ECL2 of its receptor. The data sug-
gests that the mode of interaction of CGRP8-37 with the 
CGRP receptor is likely to be more complicated than pre-
dicted from a simple consideration of the two-domain 
model [14]. In a previous structure-activity study, we 
demonstrated that mutations to residues 8 and 9 of CGRP 
gave partial agonists, challenging a simplistic notion that 
CGRP1-7 is the sole determinant of receptor activity [21].  
The current data suggests that the ECL2 interaction also 
extends beyond the extreme N-terminus of the peptide; the 
model indicates that they can interact with ECLs 2 and 3 
and so directly influence the TM bundle. This helps our 
understanding of receptor activation as well as emphasising 
the key role of ECL2 in the CGRP receptor. 
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Figure 1. Dose response curves of Cos7 cells transfected with WT 
CGRP receptor (WT CLR + R1) or alanine substitution receptor 
(mutant CLR + R1) incubated with and without CGRP8-37 (10-7 
M) stimulated with CGRP over a logarithmic concentration range 
of (10-12 M to 10-5 M). Raw cAMP values were normalized to WT 
(0M CGRP8-37) basal and Emax values. The curves show means ±  
s.e.m values of 3-5 determinations. The broken lines in the graphs 
of the mutant receptors show the fit if it is assumed that the max-
imum response is unchanged in the presence of CGRP8-37. 
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Figure 2a. % Emax values of mutants in the presence of CGRP8-37 
relative to Emax values without antagonist. Significant differ-
ences were determined using a one sample t test. * p value < 0.05. 
b) Correlation between pEC50 for CGRP and change in Emax at 
alanine mutants. 
 
Figure 3. Model of the ECL2 region of CLR, showing the 
bound N-terminus (residues 1-18) of CGRP in green. R274, 
blue; D280, red; W283, light blue; I284, yellow; D287, 
orange; T288, purple. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Differ-
ences in the 
CGRP8-37 pKd values at WT and mutant receptors Values are 
means ± s.e.m., *,** p value < 0.05, 0.01, unpaired Student’s 
t-test) 
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